The strong bone phenotype observed in genetic mouse models together with the high bone mass in patients deficient of sclerostin indicated that sclerostin might be a novel therapeutic target and encouraged the development of specific antibodies against sclerostin as a bone anabolic approach to treat osteoporosis and other bone loss conditions. The gene discussed is SOST; the disease is osteoporosis.